Literature DB >> 7841570

Possible ciprofloxacin-induced acute cholestatic jaundice.

O Sherman1, J L Beizer.   

Abstract

OBJECTIVE: To report a case of acute cholestatic jaundice in a patient who was receiving oral ciprofloxacin. CASE
SUMMARY: An 84-year-old woman residing in a long-term care facility developed acute cholestatic jaundice while being treated with ciprofloxacin for a urinary tract infection. On day 6 of ciprofloxacin therapy, she was noted to have an erythematous, pruritic rash over her chest and abdomen. At this point ciprofloxacin treatment was discontinued, as an allergy was suspected. Three days later she was noted to have jaundiced sclera and skin, and liver function test results were markedly elevated. The plasma cholesterol concentration was increased substantially; there was no decrease in plasma albumin concentration or increase in prothrombin time. The patient was treated with intravenous fluids. Within the next month, the liver function test results decreased to near normal and the patient was asymptomatic. Follow-up liver test results three months later were normal. DISCUSSION: To our knowledge, there are only a few other case reports in the literature of a possible ciprofloxacin-induced liver injury. Enoxacin, a fluorinated quinolone antibiotic similar to ciprofloxacin, was reported to cause cholestatic liver injury in one patient. The exact mechanism by which fluoroquinolones may cause liver injury is unknown.
CONCLUSIONS: We believe that this is only the second reported case of acute cholestatic jaundice resulting from ciprofloxacin therapy. Although this reaction seems to occur rarely, it is prudent to be alert for the signs and symptoms of cholestasis when administering ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841570     DOI: 10.1177/106002809402801005

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Clinical and histopathologic features of fluoroquinolone-induced liver injury.

Authors:  Eric S Orman; Hari S Conjeevaram; Raj Vuppalanchi; James W Freston; James Rochon; David E Kleiner; Paul H Hayashi
Journal:  Clin Gastroenterol Hepatol       Date:  2011-02-26       Impact factor: 11.382

Review 2.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

3.  Cholestatic jaundice induced by ciprofloxacin.

Authors:  J K Labowitz; W B Silverman
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.487

Review 4.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Ciprofloxacin-induced acute liver injury: case report and review of literature.

Authors:  Annette Zimpfer; Albert Propst; Gregor Mikuz; Wolfgang Vogel; Luigi Terracciano; Sylvia Stadlmann
Journal:  Virchows Arch       Date:  2004-01       Impact factor: 4.064

6.  A Complex Case of Cholestasis in a Patient with ABCB4 and ABCB11 Mutations.

Authors:  Mariana Ferreira Cardoso; Joana Carvalho E Branco; Vera Anapaz; Catarina Graça Rodrigues; Rita Carvalho; David Horta; Alexandra Martins; Jorge Reis
Journal:  GE Port J Gastroenterol       Date:  2017-11-25

Review 7.  Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature.

Authors:  Milan Radovanovic; Tetyana Dushenkovska; Ivan Cvorovic; Natasa Radovanovic; Vimala Ramasamy; Katarina Milosavljevic; Jelena Surla; Mladen Jecmenica; Miroslav Radulovic; Tamara Milovanovic; Igor Dumic
Journal:  Am J Case Rep       Date:  2018-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.